Research programme: oligonucleotide therapeutics - AdiuTide

Drug Profile

Research programme: oligonucleotide therapeutics - AdiuTide

Alternative Names: ATP-00001; ATP-00002; ATP-10001

Latest Information Update: 23 Jan 2014

Price : $50

At a glance

  • Originator AdiuTide Pharmaceuticals
  • Class Oligonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Cancer; Infections

Most Recent Events

  • 23 Jan 2014 Preclinical trials in Asthma in Germany before January 2014 (unspecified route)
  • 23 Jan 2014 Preclinical trials in Infections (infectious diseases) in Germany before January 2014 (unspecified route)
  • 23 Jan 2014 Preclinical trials in Cancer in Germany before January 2014 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top